Fermbox Bio, ICGEB sign licensing deal to scale yeast and enzyme technologies

Fermbox Bio has signed a technology licensing MoU with ICGEB to scale, manufacture and commercialise two India-focused biotech technologies: active dried yeast and an enzyme platform for lignocellulosic degradation. The agreement is aimed at moving the technologies into multi-100 KL fermentation systems and strengthening domestic bio-manufacturing capacity.

Why it matters: - The deal could help move two lab-developed technologies into commercial production in India. - The agreement supports larger fermentation capacity, which matters for scaling bio-based manufacturing beyond pilot stages. - The partnership fits into India’s push to expand its bioeconomy and reduce dependence on imported or chemistry-heavy inputs.

What happened: - Fermbox Bio Private Limited signed a technology licensing agreement with the International Centre for Genetic Engineering and Biotechnology, or ICGEB, New Delhi. - The MoU covers the scale-up, manufacturing and commercialisation of two ICGEB-developed technologies. - The technologies are active dried yeast and an overexpression enzyme platform for optimised lignocellulosic degradation. - The technology transfer was announced at Vigyan Tech 2026 on 11 May 2026 at BRIC-NII in New Delhi during National Technology Day celebrations. - The programme included technology transfers, license agreements and launches by participating ministries and departments. - The event was attended by Dr. Jitendra Singh, Dr. Rajesh Gokhale and Dr. Ramesh V. Sonti.

The details: - The agreement is aimed at enabling commercial translation of the technologies in multi-100 KL and larger fermentation systems. - Fermbox Bio and ICGEB will work together to assess, scale up, manufacture and commercialise the licensed technologies. - Fermbox Bio is a biotechnology research and manufacturing company based in India with a subsidiary in the USA. - Fermbox Bio uses precision fermentation and advanced biotechnology to develop bio-based products designed to reduce supply-chain exposure to harsh chemistry, forest reserves or animal-derived sources. - Fermbox Bio’s portfolio includes enzymes, lipids, proteins, flavours and colours. - The company serves energy, nutraceuticals, cosmeceuticals, and flavours and fragrances markets. - ICGEB is an intergovernmental organisation aligned with the United Nations Common System. - ICGEB focuses on research, training and technology transfer to industry.

Between the lines: - The agreement signals a shift from technology development to industrial deployment. - Multi-100 KL scale-up suggests the parties are targeting commercially meaningful volumes, not just demonstration batches. - The licensing model also points to a broader strategy of translating public-sector research into manufacturing capacity inside India.

What’s next: - Fermbox Bio and ICGEB will begin the technical work needed to validate and scale the licensed processes. - The next milestones are likely to include process assessment, manufacturing readiness and commercial rollout. - Success will depend on whether the technologies can perform consistently at larger production scales.

The bottom line: - Fermbox Bio and ICGEB are betting that Indian biotech research can move into commercial bio-manufacturing at scale.